A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study*†‡*Supported by Sandoz Pharma, Ltd.†Presented in part at the Joint Meeting of the European Society of Human Reproduction and Embryology and the European Sterility Congress Organization, Milan, Italy, August 31, 1990.‡The following investigators were participants in this French multicenter study: Philippe Jaquet, M.D., Marseille; Jean-Pierre Louvet, M.D., Toulouse; Didier Dewailly, M.D., Lille; Patrick Roger, M.D., Bordeaux; Jean-Louis Schlienger, M.D., Strasbourg; Gèrard Schaison, M.D., Paris; Pierre Hartemann, M.D., Nancy.

1992 ◽  
Vol 57 (1) ◽  
pp. 74-80 ◽  
Author(s):  
Thierry Brue ◽  
Ioana Lancranjan ◽  
Jean-Pierre Louvet ◽  
Didier Dewailly ◽  
Patrick Roger ◽  
...  
2004 ◽  
Vol 16 (6) ◽  
pp. 319-325 ◽  
Author(s):  
Pierre S. Chue ◽  
Peter D'Hoore ◽  
J. Michael Ramstack

Chronic disorders such as schizophrenia require long-term treatment programs in order to maintain patients at the lowest level of symptomatology, reduce the likelihood of psychotic relapse, and support achievement of remission and recovery. Evidence suggests that treatment with long-acting injectable antipsychotics reduces the impact of partial compliance and provides predictable release of medication, assuring continuous therapeutic coverage. Until recently, only conventional antipsychotic agents were available in long-acting formulations, thereby foregoing the advantages of the atypical class. Atypical agents which are given orally have been shown to provide long-term efficacy and tolerability benefits compared with conventional agents, but are limited by the need for daily administration. The most recent pharmacological strategy to achieve optimal maintenance treatment has been to combine the benefits of an atypical antipsychotic with delivery in a water-based long-acting formulation. The first antipsychotic to achieve this combination – long-acting risperidone – may thus represent an important advance in the optimization of long-term treatment outcomes in patients with schizophrenia.


1987 ◽  
Vol 111 (4) ◽  
pp. 548-551 ◽  
Author(s):  
Jeffrey A. Jackson ◽  
Henry B. Hahn ◽  
Charles E. Oltorf ◽  
Thomas M. O'Dorisio ◽  
Arthur I. Vinik

2017 ◽  
Vol 41 (S1) ◽  
pp. S15-S15
Author(s):  
E. Vieta

Antipsychotics are widely used for the short and long-term treatment of bipolar disorder. Depot and long-acting injectable formulations (LAIs) can be particularly useful for certain subgroups of patients. This lecture will discuss the available data from randomized controlled trials of LAIs in bipolar disorder. A recently published meta-analysis and individual studies assessing depot medications, as well as modern LAIs such as risperidone, paliperidone and aripiprazole, will be reviewed, looking carefully into the prevention of either pole of illness and tolerability. Potential indications and patient profile, based on data and clinical experience, will be discussed.Disclosure of interestThe author has not supplied his declaration of competing interest.


1988 ◽  
Vol 23 (1) ◽  
pp. 135-135 ◽  
Author(s):  
M T Tauber ◽  
J P Tauber ◽  
A G Harris ◽  
J M Lafitte ◽  
M Keddari ◽  
...  

CNS Spectrums ◽  
2012 ◽  
Vol 17 (s1) ◽  
pp. 10-21 ◽  
Author(s):  
Debbi A. Morrissette ◽  
Stephen M. Stahl

Antipsychotics are the mainstay of treatment for patients with schizophrenia. However, these medications only work if they are taken and perhaps work best if they are taken for longer periods of time than seen in typical research trials. Here we explore the idea of “time as a drug” by reviewing the data showing the potential benefits of long-term antipsychotic use. We also discuss the utility of depot antipsychotic formulations for improving the chances of attaining long-term therapeutic results.


Sign in / Sign up

Export Citation Format

Share Document